Industry News
Compumedics revenues, losses up
Compumedics' (ASX:CMP) revenues for the 2002-2003 financial year were up 62 per cent to AUD$32 million, reflecting strong growth in the company's sleep diagnostics business. [ + ]
Anadis therapy aiming to ease travellers' paths
It's a malady with many colourful names -- Montezuma's revenge, Delhi belly, the Karachi Crouch -- but traveller's diarrhoea, by any other name, has disembowelled many a costly overseas holiday or business trip. [ + ]
Patent could lead to new royalty revenue: CSL
A new US patent issued to CSL (ASX:CSL) and the University of Queensland over human papillomavirus (HPV) will lead to royalty revenue if drug giant Merck launches a vaccine for the virus in the US. [ + ]
Do you have hyperactive platelets?
A researcher at the University of Newcastle is looking for patients with type-2 diabetes who are currently not taking anti-platelet medication for a new study involving tomato juice and fish oil!
[ + ]PanBio tips profit for 2003-04
Queensland-based diagnostics company PanBio (ASX:PBO) has ended the financial year with an anticipated loss, but expects the 2003-2004 year to be profitable, said chairman Ian Sandford today. [ + ]
AustCancer finds cancer jammer molecule
Perth-based cancer therapeutics developer Australian Cancer Technology's (ASX:ACU) joint discovery project with Cambridge-based BioFocus (AIM:BIO) has designed a tiny spanner to jam the molecular works of cancer cells that evade conventional chemotherapy and radiotherapy. [ + ]
Hunt for SARS source far from over: researcher
Virologists have some suspects, but the animal that originally hosted the lethal coronavirus that causes severe acute respiratory syndrome (SARS) in humans remains unidentified. [ + ]
New online publishing system boosts access to resources
In a boost for Australasian research, leading e-publisher RMIT Publishing has announced the release of a new online publishing and content management system to provide researchers with better access to a wide range of Australasian online resources currently available on its Informit Online service.
[ + ]S&P raises ResMed ratings
Standard & Poor's ratings services has raised its corporate credit rating on ResMed (ASX:RMD) to 'BB-' from 'B+', and raised its senior subordinated debt rating on the company to 'B' from 'B-'. [ + ]
Qld's Élan joins with US Meditech on biohazard
Queensland company Élan BioDynamics, a wholly owned subsidiary of the Élan Group, has entered a joint venture with US company Meditech Pharmaceuticals to commercialise a system for detection of biological hazards including aflatoxin, and anthrax. [ + ]
Pest solution goes back for mouse-to-mouse resuscitation
Plans to conduct the first contained field trial of a transgenic virus designed to prevent episodic plagues of the house mouse in the Australian wheat belt have been set back while researchers work to improve its transmission under field conditions [ + ]
CogState ponders market options
Unlisted Melbourne company CogState is contemplating a float on the Australian Stock Exchange, according to CEO Dr Peter Bick. [ + ]
Sol-gel diversity revealed at ANSTO-sponsored meeting
In the last week of August, Australia's first international meeting on sol-gel science and technology revealed the diversity of a scientific process which can produce ceramic and glass materials at low temperatures for use in areas ranging from biotechnology, telecommunications, protective coatings, nanotechnology, environmental monitoring and waste clean-up.
[ + ]Gradipore's loss slightly higher than expected
Sydney bioseparations specialist Gradipore (ASX:GDP) has reported an operating loss for 2002-03 of AUD$16.7 million, down from an $18.5 million loss the previous year but slightly higher than the figure forecast by the company in May. [ + ]
Prima touts human trials hopes for vaccine tech
Prima Biomed subsidiary PanVax is planning to test its DCtag adjuvant technology with an existing marketed vaccine in human clinical trials, aiming to demonstrate enhanced immunogenicity of the re-engineered vaccine compared to existing formulations. [ + ]